title: Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease.
abstract: Asymptomatic throat carriage of Neisseria meningitidis is common in healthy individuals. In unusual cases, the bacteria become invasive, resulting in life-threatening disease. Effective meningococcal serogroup B (MnB) vaccines should provide broad protection against disease-causing strains and may confer indirect protection by impacting carriage and subsequent transmission. Factor H binding proteins (fHBPs), components of MnB vaccines in development, are classified into two immunologically distinct subfamilies (A and B). fHBP variants of MnB strains carried by adolescents are similar to those detected in infants with MnB disease. A vaccine containing subfamily A and B fHBP variants elicited bactericidal antibody responses (titers ≥ 1:4) against MnB strains expressing fHBP variants common to carriage strains and strains that cause disease in adolescents and infants in 75-100% of adolescent study subjects. This suggests that the bivalent fHBP vaccine has the potential to provide protection against invasive MnB strains and interrupt meningococcal carriage, which may also reduce infant MnB disease.
authors.affiliation: Pfizer Vaccine Research; Pearl River, NY USA.
authors.forename: Annaliesa S
authors.initials: AS
authors.lastname: Anderson
authors.forename: Li
authors.initials: L
authors.lastname: Hao
authors.forename: Qin
authors.initials: Q
authors.lastname: Jiang
authors.forename: Shannon L
authors.initials: SL
authors.lastname: Harris
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Jones
authors.forename: John L
authors.initials: JL
authors.lastname: Perez
authors.forename: Laura
authors.initials: L
authors.lastname: York
authors.forename: Joseph
authors.initials: J
authors.lastname: Eiden
authors.forename: Kathrin U
authors.initials: KU
authors.lastname: Jansen
mesh_terms: D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology*; D016470:Bacteremia / Q000517:prevention & control*; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology*; D001770:Blood Bactericidal Activity; D002353:Carrier State / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D022401:Meningococcal Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; C484699:factor H-binding protein, Neisseria meningitidis